ArcticZymes Technologies - Primary insider trading
ArcticZymes Technologies ASA (AZT) · publisert 8. november 2024 kl. 08:18 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass |
|---|---|---|---|---|---|---|---|
| Frank Mathias | Styreleder | Kjøp | 2 000 | 1,194 EUR | 7. november 2024 | NO0010014632 | XOSL |
Vedlegg
- Notification_trading_Frank_Mathias2.pdf (application/pdf, originaldokument)
Meldingstekst
(Tromsø 08 November 2024) Frank Mathias, Chairman of the Board has on 07
November purchased 2.000 shares in ArcticZymes Technologies ASA for EUR 1.194
per share. Following this transaction holds Mr. Mathias 9.000 shares in the
company.
This information is subject to the disclosure requirements in articles 19 of the
Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the
Norwegian Securities Trading Act.
For additional information, please contact
Børge Sørvoll
CFO
+4795290187
ir@arcticzymes.com
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker.
Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.
ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.
For more information, please visit the website: www.arcticzymes.com